The Treatment Effects of Empagliflozin on Renal Outcomes in Cardiorenal Syndrome Type 1

NCT06030843 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

200

Enrollment

OTHER

Sponsor class

Conditions

Empagliflozin in Cardiorenal Syndrome Type 1

Interventions

DRUG: Empagliflozin 10 MG
DRUG: Placebo

Sponsor

Chulalongkorn University